You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023656062
Dec 2023183031
Jan 2024274026
Feb 2024124036
Mar 2024126030
Apr 2024130041
May 2024120026
Jun 2024182019
Jul 2024146024
Aug 2024164022
Sep 2024159032
Oct 2024136031
Nov 2024160027
Dec 2024178025
Jan 2025207030
Feb 202570041
Mar 20250027
Apr 20250020
May 20250024
Jun 20250014
Total30150588